Moderna Surges After Historic Phase 3 Success for First mRNA Cancer Therapy
Moderna shares surged after positive Phase 3 results for the first successful mRNA cancer therapy, adding more than $50 billion in market value.
#Biotechnology
Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "biotechnology", collected in one continuously updated archive.
Related Posts
Moderna Shares Soar After Personalized mRNA Cancer Vaccine Succeeds in Phase III Trial
Moderna and Merck reported the first successful Phase III trial of a personalized mRNA cancer vaccine, sending Moderna shares sharply higher.
AI Longevity Startup Gero Raises Additional $17 Million to Develop Anti-Aging Drugs
Gero has secured $17 million in new funding, bringing its total capital raised to $34 million as the company advances AI-driven drug discovery focused on aging and chronic diseases.
Recursion Pharmaceuticals
By
Emma Clarke
• 3 mins read
Recursion Pharmaceuticals, Inc. is an American clinical-stage biotechnology company that uses automated experiments, biological datasets, computing, and machine learning in drug discovery. It develops its own medicine candidates and conducts research programs with pharmaceutical partners.
Biohacker Bryan Johnson Says Humans Could Achieve Immortality by 2039 Using AI and Radical
By
Benjamin Harper
• 2 mins read
Tech entrepreneur and biohacker Bryan Johnson claims artificial intelligence and experimental medicine could make human immortality achievable within 15 years, despite unresolved risks.